It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Human tubulin beta class IVa (TUBB4A) is a member of the β-tubulin family. In most normal tissues, expression of TUBB4A is little to none, but it is highly expressed in human prostate cancer. Here we show that high expression levels of TUBB4A are associated with aggressive prostate cancers and poor patient survival, especially for African-American men. Additionally, in prostate cancer cells, TUBB4A knockout (KO) reduces cell growth and migration but induces DNA damage through increased γH2AX and 53BP1. Furthermore, during constricted cell migration, TUBB4A interacts with MYH9 to protect the nucleus, but either TUBB4A KO or MYH9 knockdown leads to severe DNA damage and reduces the NF-κB signaling response. Also, TUBB4A KO retards tumor growth and metastasis. Functional analysis reveals that TUBB4A/GSK3β binds to the N-terminal of MYH9, and that TUBB4A KO reduces MYH9-mediated GSK3β ubiquitination and degradation, leading to decreased activation of β-catenin signaling and its relevant epithelial-mesenchymal transition. Likewise, prostate-specific deletion of Tubb4a reduces spontaneous tumor growth and metastasis via inhibition of NF-κB, cyclin D1, and c-MYC signaling activation. Our results suggest an oncogenic role of TUBB4A and provide a potentially actionable therapeutic target for prostate cancers with TUBB4A overexpression.
The β-tubulin family protein TUBB4A is highly expressed in cancer but it’s molecular role is unclear. Here, the authors show that TUBB4A is required to protect the nucleus from genomic instability during migration and that it’s over expression promotes cancer progression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Alabama at Birmingham, Department of Genetics, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)
2 University of Alabama at Birmingham, Department of O’Neal Comprehensive Cancer Center, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)
3 University of Alabama at Birmingham, Department of O’Neal Comprehensive Cancer Center, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, Department of Pathology, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)
4 University of Alabama at Birmingham, Department of O’Neal Comprehensive Cancer Center, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, Department of Urology, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, Department of Radiology, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)
5 University of Alabama at Birmingham, Department of O’Neal Comprehensive Cancer Center, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, Department of Medicine, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)
6 Mercer University School of Medicine, Department of Biomedical Sciences, Savannah, USA (GRID:grid.259907.0)
7 Dana Farber Cancer Institute, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
8 University of Alabama at Birmingham, Department of Genetics, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187); University of Alabama at Birmingham, Department of O’Neal Comprehensive Cancer Center, Birmingham, USA (GRID:grid.265892.2) (ISNI:0000000106344187)